Welcome to our spotlight on MSCs!

Quick access to all the content in the latest RegMedNet spotlight, including expert editorials, peer-reviewing journal content and more.

Go to the profile of RegMedNet
May 27, 2018

Visit the spotlight

Since their isolation in the 1960s and 1970s, mesenchymal stem cells (MSCs) have been a popular target for regenerative therapies. The first clinical trial utilizing MSCs was complete in 1995 and over the past decade, there have been huge developments in our understanding of the method of action by which they can repair and regenerative tissue. 

MSCs can be harvested from several human tissues, or derived from induced pluripotent stem cells (iPSCs), and can differentiate into a range of tissue-specific cells. Various studies have also shown the MSCs, unlike iPSCs, show few oncogenic properties, potentially making them safer as therapeutic agents. Their strong capacity for differentiation also makes MSCs useful as a tool to model disease progression and assess drug efficacy. 

The spotlight will aim to review the current challenges in the production of MSCs with a focus on consistency, safety and efficacy. We will also look into the clinical applications of MSCs for regenerative medicine and how these therapies are going to evolve and change healthcare in the coming years.

Visit the spotlight - new posts weekly!


Editorials and interviews




Journal articles


Go to the profile of RegMedNet


eCommunity, Future Science Group

RegMedNet is a networking site where users can share their knowledge and insights. This profile will share some content and updates from the RegMedNet team, including webinars, news and journal articles.

No comments yet.